Your session is about to expire
← Back to Search
Monoclonal Antibodies
Ivonescimab + Pembrolizumab for Lung Cancer
Phase 3
Recruiting
Research Sponsored by Summit Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
No prior systemic treatment for metastatic NSCLC
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Must not have
Histologic or cytopathologic evidence of the presence of small cell lung carcinoma, or non-squamous NSCLC histology
Known actionable genomic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 or genes for which first-line approved therapies are available
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 4 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing two treatments for advanced lung cancer. One uses a new drug, Ivonescimab, and the other uses an existing drug, Pembrolizumab, both combined with chemotherapy. The goal is to see which treatment helps patients live longer and has fewer side effects.
Who is the study for?
Adults with metastatic squamous non-small cell lung cancer (NSCLC) who have not had previous treatments for their advanced disease. Participants must have a certain level of PD-L1 expression, be in good physical condition (ECOG score 0 or 1), and expect to live at least three more months. They cannot join if they have small cell lung carcinoma, non-squamous NSCLC, major blood vessel involvement by the tumor, or known specific genetic alterations.
What is being tested?
This Phase 3 trial is testing Ivonescimab combined with chemotherapy against Pembrolizumab with chemotherapy as first-line treatment options for metastatic squamous NSCLC. The main goal is to see which treatment helps patients live longer without their cancer getting worse.
What are the potential side effects?
Possible side effects include reactions at the injection site, immune-related issues such as inflammation in various organs due to an overactive immune response, fatigue, and complications related to chemotherapy like nausea and low blood counts.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I haven't had any systemic treatment for my advanced lung cancer.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My lung cancer has spread to other parts of my body.
Select...
My lung cancer is confirmed to be squamous type.
Select...
My tumor shows a certain level of PD-L1 expression.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My lung cancer is confirmed to be either small cell or non-squamous non-small cell.
Select...
My cancer has specific genetic changes in EGFR, ALK, or ROS1.
Select...
I have received treatment for my lung cancer after it spread.
Select...
My cancer has spread to major blood vessels or caused holes in the tumor.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 4 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Overall Survival (OS)
Secondary study objectives
Adverse Event (AE)
Progression-Free Survival (PFS)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A - Ivonescimab and chemotherapyExperimental Treatment1 Intervention
Subject will receive ivonescimab and chemotherapy
Group II: Arm B - Pembrolizumab and chemotherapyActive Control1 Intervention
Subject will receive pembrolizumab and chemotherapy
Find a Location
Who is running the clinical trial?
Summit TherapeuticsLead Sponsor
12 Previous Clinical Trials
2,197 Total Patients Enrolled